Rani Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 16-11-2024
- Paid Up Capital ₹ 7.02 M
as on 16-11-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.95 Cr
as on 16-11-2024
- Revenue 203.80%
(FY 2023)
- Profit 223.32%
(FY 2023)
- Ebitda 14.62%
(FY 2023)
- Net Worth 8.65%
(FY 2023)
- Total Assets -32.59%
(FY 2023)
About Rani Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.02 M.
The company currently has active open charges totaling ₹4.95 Cr.
Sandhyarani Pulayarthi and Venkata Chinamuttevi serve as directors at the Company.
- CIN/LLPIN
U24297TG2009PTC063385
- Company No.
063385
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rani Life Sciences Private Limited offer?
Rani Life Sciences Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Aldehydes, Nutraceuticals & Dietary Supplements, Nutraceuticals, Chemical Intermediates.
Who are the key members and board of directors at Rani Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Chinamuttevi  | Managing Director | 30-Apr-2010 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandhyarani Pulayarthi | Director | 22-Apr-2009 | Current |
Financial Performance of Rani Life Sciences.
Rani Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 203.8% increase. The company also saw a substantial improvement in profitability, with a 223.32% increase in profit. The company's net worth moved up by a moderate rise of 8.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rani Life Sciences?
In 2023, Rani Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 18 Dec 2023 | ₹1.00 Cr | Open |
Sidbi Creation Date: 02 Dec 2022 | ₹4.70 M | Open |
Sidbi Creation Date: 03 Mar 2022 | ₹5.00 M | Open |
How Many Employees Work at Rani Life Sciences?
Unlock and access historical data on people associated with Rani Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rani Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rani Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
